- Home
- INTS vs ACXP Comparison
INTS vs ACXP Comparison
Compare INTS & ACXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INTS
- ACXP
- Stock Information
- Founded
- INTS 2012
- ACXP 2017
- Country
- INTS United States
- ACXP United States
- Employees
- INTS N/A
- ACXP N/A
- Industry
- INTS Biotechnology: Pharmaceutical Preparations
- ACXP Biotechnology: Pharmaceutical Preparations
- Sector
- INTS Health Care
- ACXP Health Care
- Exchange
- INTS Nasdaq
- ACXP Nasdaq
- Market Cap
- INTS 9.4M
- ACXP 8.4M
- IPO Year
- INTS 2023
- ACXP 2021
- Fundamental
- Price
- INTS $0.32
- ACXP $0.53
- Analyst Decision
- INTS Strong Buy
- ACXP Strong Buy
- Analyst Count
- INTS 3
- ACXP 2
- Target Price
- INTS $8.50
- ACXP $10.00
- AVG Volume (30 Days)
- INTS 2.6M
- ACXP 18.5M
- Earning Date
- INTS 08-07-2025
- ACXP 08-08-2025
- Dividend Yield
- INTS N/A
- ACXP N/A
- EPS Growth
- INTS N/A
- ACXP N/A
- EPS
- INTS N/A
- ACXP N/A
- Revenue
- INTS N/A
- ACXP N/A
- Revenue This Year
- INTS N/A
- ACXP N/A
- Revenue Next Year
- INTS N/A
- ACXP N/A
- P/E Ratio
- INTS N/A
- ACXP N/A
- Revenue Growth
- INTS N/A
- ACXP N/A
- 52 Week Low
- INTS $0.26
- ACXP $0.30
- 52 Week High
- INTS $5.10
- ACXP $3.33
- Technical
- Relative Strength Index (RSI)
- INTS 37.08
- ACXP 47.99
- Support Level
- INTS $0.28
- ACXP $0.52
- Resistance Level
- INTS $0.32
- ACXP $0.63
- Average True Range (ATR)
- INTS 0.06
- ACXP 0.09
- MACD
- INTS 0.01
- ACXP 0.00
- Stochastic Oscillator
- INTS 7.43
- ACXP 17.33
About INTS Intensity Therapeutics Inc. Common stock
Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with unmet medical need.
About ACXP Acurx Pharmaceuticals Inc.
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration. The company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum. The Company's segment consists of the development of clinical and preclinical product candidates for the development of the Company's proprietary new therapies.